MEI Pharma (MEIP)
NASDAQ:MEIP

MEI Pharma Stock Price & Analysis

939 Followers

MEIP Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.28 - $3.55
Previous Close$0.37
Volume525.23K
Average Volume (3M)747.63K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$138.37M
Total Debt (Recent Filing)$13.68M
Price to Earnings (P/E)-0.8
Beta0.40
Next EarningsFeb 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.45
Shares Outstanding133,260,865
R-Squared0.05
Standard Deviation0.21
10 Day Avg. Volume976,686
30 Day Avg. Volume747,629
Price to Book (P/B)1.32
Price to Sales (P/S)1.03
Price to Cash Flow (P/CF)6.70
P/FCF Ratio-0.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside1994.29% Upside
Rating ConsensusStrong Buy
Alpha-0.02
Number of Analyst Covering3


Financials


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

MEIP FAQ

What was MEI Pharma’s price range in the past 12 months?
MEI Pharma lowest stock price was $0.28 and its highest was $3.55 in the past 12 months.
    What is MEI Pharma’s market cap?
    Currently, no data Available
    When is MEI Pharma’s upcoming earnings report date?
    MEI Pharma’s upcoming earnings report date is Feb 09, 2023 which is in 71 days.
      How were MEI Pharma’s earnings last quarter?
      MEI Pharma released its earnings results on Nov 14, 2022. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.168 by $0.048.
        Is MEI Pharma overvalued?
        According to Wall Street analysts MEI Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does MEI Pharma pay dividends?
          MEI Pharma does not currently pay dividends.
          What is MEI Pharma’s EPS estimate?
          MEI Pharma’s EPS estimate is -$0.14.
            How many shares outstanding does MEI Pharma have?
            MEI Pharma has 133,260,860 shares outstanding.
              What happened to MEI Pharma’s price movement after its last earnings report?
              MEI Pharma reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.168. Following the earnings report the stock price went up 3.03%.
                Which hedge fund is a major shareholder of MEI Pharma?
                Among the largest hedge funds holding MEI Pharma’s share is Carlson Capital LP. It holds MEI Pharma’s shares valued at 444K.

                  ---

                  MEI Pharma Stock Smart Score

                  5
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -86.01%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -154.97%
                  Trailing 12-Months
                  Asset Growth
                  -7.24%
                  Trailing 12-Months
                  The MEI Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  MEI Pharma

                  MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis